| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| keynote 522 breast cancer trial | 1.47 | 1 | 664 | 6 |
| keynote 522 clinical trial | 1.45 | 1 | 2399 | 6 |
| keynote 522 triple negative breast cancer | 1.1 | 0.5 | 6116 | 2 |
| keynote trial breast cancer | 1.08 | 0.2 | 1461 | 34 |
| keynote 522 trial protocol | 0.56 | 0.4 | 2027 | 18 |
| keynote 522 trial regimen | 1.19 | 0.5 | 4062 | 50 |
| keynote 522 trial design | 0.87 | 0.1 | 7128 | 87 |
| keynote 522 updated results | 0.8 | 0.5 | 4204 | 48 |
| keynote 522 chemo regimen | 0.35 | 0.6 | 584 | 36 |
| keynote 522 fda approval | 1.22 | 1 | 3364 | 56 |
| keynote 522 treatment plan | 1.53 | 0.6 | 7491 | 58 |
| keynote 355 breast cancer | 1.74 | 0.1 | 6291 | 96 |
| keynote 756 breast cancer | 1.07 | 0.4 | 4587 | 17 |
| what is keynote 522 regimen | 0.75 | 0.4 | 3913 | 33 |
| keynote 522 protocol nejm | 0.59 | 0.8 | 5911 | 45 |
| keynote breast cancer neoadjuvant | 0.28 | 0.9 | 3483 | 60 |
| keynote triple negative breast cancer | 1.01 | 1 | 1457 | 72 |
| keynote breast cancer metastatic | 1.05 | 0.1 | 7379 | 41 |
| keynote-522 fda | 1.72 | 0.7 | 1027 | 75 |
| keynote 522 overall survival | 1.1 | 0.9 | 83 | 3 |
| keynote 522 regimen schedule | 1.06 | 0.4 | 3789 | 31 |
| keynote-522 | 0.84 | 0.6 | 3189 | 51 |
